We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

174 hedge funds and large institutions have $1.86B invested in Celldex Therapeutics in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 66 increasing their positions, 48 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more call options, than puts

Call options by funds: $24.9M | Put options by funds: $17.1M

38% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 48

2.75% more ownership

Funds ownership: 108.33% → 111.07% (+2.7%)

6% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 36

1% less funds holding

Funds holding: 176 → 174 (-2)

24% less capital invested

Capital invested by funds: $2.44B → $1.86B (-$579M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
174
Holders Change
-2
Holders Change %
-1.14%
% of All Funds
2.29%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
34
Increased
66
Reduced
48
Closed
36
Calls
$24.9M
Puts
$17.1M
Net Calls
+$7.83M
Net Calls Change
-$17.5M

Top Buyers

1
JFG
Jefferies Financial Group
New York
+$64.4M
2
KCM
Kynam Capital Management
New Jersey
+$43.6M
3
DTC
Deep Track Capital
Connecticut
+$41.8M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$25.7M
5
Morgan Stanley
Morgan Stanley
New York
+$24.7M

Top Sellers

1
CC
Commodore Capital
New York
-$55M
2
Jennison Associates
Jennison Associates
New York
-$45M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$31.7M
4
PCH
Polar Capital Holdings
United Kingdom
-$31.4M
5
LGM
Logos Global Management
California
-$30.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
CSC
151
Caldwell Sutter Capital
California
$8.85K – – –
FHA
152
First Horizon Advisors
Tennessee
$8.41K – – –
JSAM
153
J. Safra Asset Management
New York
$7.84K +$3.5K +129 +70%
SAM
154
Smartleaf Asset Management
Massachusetts
$7.61K +$3.07K +113 +59%
LC
155
Lindbrook Capital
California
$6.87K +$2.91K +107 +65%
S
156
SignatureFD
Georgia
$6.49K +$3.37K +124 +93%
ACM
157
Aster Capital Management
United Arab Emirates
$4.8K +$5.16K +190 New
FFA
158
Farther Finance Advisors
California
$3.03K -$5.51K -203 -63%
CAM
159
Close Asset Management
United Kingdom
$3K – – –
RIL
160
Rothschild Investment LLC
Illinois
$2.65K +$1.22K +45 +75%
BIG
161
Brooklyn Investment Group
New York
$2.48K +$2.66K +98 New
RA
162
Rise Advisors
New York
$2.1K – – –
Carson Wealth (CWM LLC)
163
Carson Wealth (CWM LLC)
Nebraska
$2K -$2.01K -74 -54%
PA
164
Parallel Advisors
California
$2K +$1.55K +57 +259%
QCG
165
Quadrant Capital Group
Ohio
$1.69K +$1.82K +67 New
SWM
166
Spire Wealth Management
Virginia
$1.26K – – –
Amundi
167
Amundi
France
$1.11K +$1.14K +42 New
GI
168
GAMMA Investing
California
$1.11K -$190 -7 -14%
TFGT
169
TS Financial Group (TSFG)
Illinois
$1K – – –
SS
170
SBI Securities
Japan
$758 +$815 +30 New
AF
171
Allworth Financial
California
$437 +$489 +18 New
SIS
172
Strategic Investment Solutions
Illinois
$198 – – –
PNC Financial Services Group
173
PNC Financial Services Group
Pennsylvania
$177 -$6.47K -238 -97%
CC
174
Commodore Capital
New York
– -$55M -1,618,937 Closed
Jennison Associates
175
Jennison Associates
New York
– -$45M -1,324,410 Closed
5 6
7
8 9

CLDX Hedge Fund Activity: Q4 2024 in Review

174 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2024, worth a combined $1.86B — down 24% from $2.44B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of CLDX and 34 opened new positions — a net loss of 2 holders — while 48 trimmed existing stakes and 66 added.

The largest buyer was Jefferies Financial Group, adding an estimated $64.4M. The largest seller was Commodore Capital, exiting entirely with an estimated $55M sold.

  • 174 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2024, down from 176 in Q3 2024.
  • Funds reported $1.86B of Celldex Therapeutics stock for Q4 2024, down 24% quarter-over-quarter.
  • 34 funds opened new Celldex Therapeutics positions in Q4 2024 and 36 closed out, a net change of -2 holders.
  • The largest Celldex Therapeutics buyer in Q4 2024 was Jefferies Financial Group, an estimated $64.4M added.
  • The largest Celldex Therapeutics seller in Q4 2024 was Commodore Capital, an estimated $55M sold.

Based on aggregated 13F filings for Q4 2024.